Celularity Inc. Stock

CELU

US1511902041

Pharmaceuticals

Market Closed - Nasdaq 01:00:00 11/11/2026 +04			5-day change	1st Jan Change
0.7110 ^USD	-6.41%		-11.40%	-35.95%

10-29	Celularity Inc. and Vesalius Longevity Labs Inc. Sign Exclusive Collaboration for Peptual Peptide Apis Manufactured in the United States	CI
10-21	Celularity Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Analysts' recommendations: Celularity Inc.

30/01/23	HC Wainwright Lowers Price Target on Celularity to $2.50 From $15, Maintains Buy Rating	MT
30/01/23	Morgan Stanley Downgrades Celularity to Underweight From Equalweight, Adjusts Price Target to $1 From $5	MT
22/12/22	Oppenheimer Downgrades Celularity to Perform From Outperform, Removes $6 Price Target	MT
14/11/22	Oppenheimer Adjusts Celularity Price Target to $6 From $8, Maintains Outperform Rating	MT
12/09/22	Morgan Stanley Trims Celularity's Price Target to $5 From $8, Keeps Equalweight Rating	MT

More recommendations

Press Releases: Celularity Inc.

10-29	Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States	BU
10-21	Celularity : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
09-30	Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner	AQ
09-30	Celularity : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
09-29	Celularity Announces Naveen Jain to Join Board of Directors	AQ

More press releases

News in other languages: Celularity Inc.

07/08/24	Cellectis : nomination d'un nouveau directeur médical
07/08/24	Cellectis : nomination d'un nouveau directeur médical
13/01/23	Celularity et CH Trading Group annoncent la conclusion d'un accord de distribution de produits avec Tamer Group qui sera leur distributeur exclusif en Arabie Saoudite
13/01/23	Celularity et CH Trading Group annoncent un accord de distribution territoriale au Moyen-Orient
05/12/22	Robert J. Hariri, M.D., Ph.D., PDG de Celularity, discute « l’utilisation de la science et de la technologie pour prolonger la longévité humaine en bonne santé » à la conférence FII

More news

Managers and Directors: Celularity Inc.

Manager	Title	Age	Since
Robert Hariri Gordon CEO	Chief Executive Officer	66	01/01/2016
John Sprague DFI	Director of Finance/CFO	67	27/02/2026
K Fletcher CMP	Compliance Officer	42	01/07/2021

Director	Title	Age	Since
Robert Hariri Gordon CHM	Chairman	66	01/01/2016
Peter Diamandis BRD	Director/Board Member	64	01/07/2017
Steven Gordon BRD	Director/Board Member	58	19/06/2026

More insiders

Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Its IMPACT manufacturing platform is a fully integrated process designed to optimize the speed of the sourcing of placentas from full-term healthy informed consent donors through the use of proprietary processing methods, cell selection, product-specific chemistry, manufacturing and control (CMC), advanced cell manufacturing and cryopreservation. It also provides contract manufacturing and development services to third parties.

Employees

115

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
10/11/26	$0.7110	-6.41%	102,141
09/11/26	$0.7597	-0.05%	151,279
06/11/26	$0.7601	+4.80%	60,564
05/11/26	$0.7253	-10.32%	168,256
04/11/26	$0.8088	-1.02%	72,008

Delayed Quote Nasdaq

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Celularity Inc.

Company calendar

Stock Market
Stocks
CELU Stock

Market Cap	24.65M 22.08M 20.33M 18.48M 34.97M 2.32B 35.92M 243M 96.97M 1.24B 92.53M 90.55M 3.91B	P/E 2024	-0.79x	P/E 2025	-0.31x
Enterprise Value	93.19M 83.45M 76.87M 69.87M 132M 8.75B 136M 920M 367M 4.68B 350M 342M 14.79B	EV / Sales 2024	2.12x	EV / Sales 2025	3.77x
Free-Float	66.73%	Yield 2024 *	-	Yield 2025	-

10-29	Celularity Inc. and Vesalius Longevity Labs Inc. Sign Exclusive Collaboration for Peptual Peptide Apis Manufactured in the United States	CI
10-21	Celularity Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
09-30	Celularity Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
09-30	Celularity Inc. Announces Appointment of Naveen Jain as Director	CI
09-28	Celularity Inc. Announces Resignation of Geoffrey Ling from the Board, Effective September 24, 2026	CI
09-24	Celularity Inc. Announces Appointment of Philip A. Barach to Board	CI
09-23	Celularity Inc. announced that it expects to receive $25 million in funding	CI
08-27	Celularity Inc. And MuseCell Innovations Pte. Ltd. Announce U.S. Manufacturing Collaboration For The Dezawa MuseCell Platform	CI
08-20	NexGel Files to Register 15.25 Million Shares From Note Conversions	MT
08-08	Celularity Inc Announces Termination of Rick Gonzalez from Chief Commercial Officer, Effective August 5, 2026	CI
06-30	Celularity Inc. Announces Resignation of Vincent LeVien as Director, Effective June 26, 2026	CI
06-30	Celularity Inc. Enters into a Loan Agreement with the Philip & Daniele Barach Family Trust	CI
06-26	Celularity Appoints Chief Operating Officer	MT

1 day	-6.41%
1 week	-11.40%
Current month	-11.14%
1 month	-54.42%
3 months	+1.47%
6 months	-19.20%
Current year	-35.95%

1 week	0.7	0.87
1 month	0.66	1.57
Current year	0.56	2.55
1 year	0.56	2.55
3 years	0.56	7.97
5 years	0.56	131.86
10 years	0.56	134

Date	Insider	Type	Main position	Quantity	% Market Cap.
23/09/26	Philip A Barach	Others		6,425,301	26.8288%
23/09/26	Philip A Barach	Others	Director	6,425,301	26.8288%
23/09/26	Philip A Barach	Others		6,425,301	26.8288%

Celularity Inc. Stock

Stocks

CELU

US1511902041

Pharmaceuticals

Valuation: Celularity Inc.

Chart: Celularity Inc.

Latest news: Celularity Inc.

Analysts' recommendations: Celularity Inc.

Press Releases: Celularity Inc.

News in other languages: Celularity Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Celularity Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELULARITY INC.	-6.41%	-11.40%	-60.06%	-67.17%	24.65M
ELI LILLY AND COMPANY	+1.44%	+1.51%	+54.95%	+142.22%	1,258B
JOHNSON & JOHNSON	-0.47%	+3.78%	+50.50%	+90.46%	679B
ABBVIE INC.	+0.20%	+1.75%	+34.10%	+112.90%	518B
ROCHE HOLDING AG	+0.17%	+1.16%	+49.70%	+68.75%	390B
MERCK & CO., INC.	-0.48%	-0.21%	+71.59%	+44.61%	367B
NOVARTIS AG	+0.76%	+2.25%	+31.84%	+59.53%	307B
ASTRAZENECA PLC	-1.29%	+0.17%	+7.63%	+33.04%	293B
AMGEN INC.	0.00%	-0.05%	+45.29%	+76.18%	252B
GILEAD SCIENCES, INC.	+0.92%	+0.32%	+43.78%	+127.89%	210B
Average	-0.52%	+0.41%	+32.93%	+68.84%	427B
Weighted average by Cap.	+0.36%	+1.18%	+46.64%	+97.34%

	2024	2025
Net sales	54.22M 48.55M 44.72M 40.65M 76.91M 5.09B 79M 535M 213M 2.72B 203M 199M 8.6B	26.55M 23.77M 21.9M 19.91M 37.66M 2.49B 38.69M 262M 104M 1.33B 99.65M 97.52M 4.21B
Net income	-57.89M -51.84M -47.75M -43.4M -82.12M -5.44B -84.35M -571M -228M -2.91B -217M -213M -9.19B	-91.72M -82.13M -75.65M -68.76M -130M -8.61B -134M -905M -361M -4.61B -344M -337M -14.56B
Net Debt	68.1M 60.98M 56.17M 51.05M 96.59M 6.4B 99.22M 672M 268M 3.42B 256M 250M 10.81B	68.54M 61.37M 56.53M 51.38M 97.22M 6.44B 99.86M 676M 270M 3.44B 257M 252M 10.88B

Markets		Quality
Nasdaq	CELU	Delayed
CBOE	CELU	Real-time